THESE PRODUCTS ARE INTENDED FOR SLOW INTRAVENOUS USE ONLY. RAPID INTRAVENOUS ADMINISTRATION MAY RESULT IN CHEST WALL RIGIDITY. NOT FOR INTRATHECAL OR EPIDURAL USE.
The usual adult dose of 10 mg every 4 hours, depending on the severity of the condition and the patient's response. The usual individual dose range is 5 to 15 mg. The usual daily dose range is 12 to 120 mg.
Analgesic - Intravenous, 50 to 100 µg (0.05 to 0.1 mg) per kg of body weight, administered very slowly. Not to exceed 10 mg per dose.
Large doses (0.5 to 3 mg/kg) of morphine are administered intravenously as the sole anesthetic or with a suitable anesthetic agent. The patients are given oxygen and cardiovascular function is not depressed by morphine, as long as adequate ventilation is maintained.
Prior to the initiation of the morphine infusion (in concentrations between 0.2 to 1 mg/mL), a loading dose of 15 mg or higher of morphine sulfate may be administered by intravenous push to alleviate pain.
The infusion dosage range is 0.8 mg/hr to 80 mg/hr, though doses of up to 144 mg/hr have been used. Thus, for the 1 mg/mL solution, the infusion may be run from 0.8 mL /hr to 80 mL /hr, and for the 0.5 mg/mL solution, the infusion may be run from 1.6 mL /hr to 160 mL /hr.
A constant infusion rate must be maintained with an infusion pump in order to assure proper dosage control. Care must be taken to avoid overdosage (respiratory depression) or abrupt cessation of therapy, which may give rise to withdrawal symptoms.
Administration of Morphine Sulfate Injection should be limited to use by those familiar with the management of respiratory depression.
NOTE: Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.
EXAMPLES OF INFUSION PREPARATION:
| Concentrate | Diluent | Final Concentration |
|---|---|---|
| Morphine Sulfate Injection, USP | Dextrose 5% in Water | Morphine Sulfate |
| 25 mg/mL | ||
| 10 mL | 490 mL | 0.5 mg/mL |
| 20 mL | 480 mL | 1.0 mg/mL |
| 40 mL | 960 mL | 1.0 mg/mL |
| Morphine Sulfate Injection, USP | ||
| 50 mg/mL | ||
| 10 mL | 990 mL | 0.5 mg/mL |
| 20 mL | 980 mL | 1.0 mg/mL |
THESE PRODUCTS ARE INTENDED FOR SLOW INTRAVENOUS USE ONLY. RAPID INTRAVENOUS ADMINISTRATION MAY RESULT IN CHEST WALL RIGIDITY. NOT FOR INTRATHECAL OR EPIDURAL USE.
The usual adult dose of 10 mg every 4 hours, depending on the severity of the condition and the patient's response. The usual individual dose range is 5 to 15 mg. The usual daily dose range is 12 to 120 mg.
Analgesic - Intravenous, 50 to 100 µg (0.05 to 0.1 mg) per kg of body weight, administered very slowly. Not to exceed 10 mg per dose.
Large doses (0.5 to 3 mg/kg) of morphine are administered intravenously as the sole anesthetic or with a suitable anesthetic agent. The patients are given oxygen and cardiovascular function is not depressed by morphine, as long as adequate ventilation is maintained.
Prior to the initiation of the morphine infusion (in concentrations between 0.2 to 1 mg/mL), a loading dose of 15 mg or higher of morphine sulfate may be administered by intravenous push to alleviate pain.
The infusion dosage range is 0.8 mg/hr to 80 mg/hr, though doses of up to 144 mg/hr have been used. Thus, for the 1 mg/mL solution, the infusion may be run from 0.8 mL /hr to 80 mL /hr, and for the 0.5 mg/mL solution, the infusion may be run from 1.6 mL /hr to 160 mL /hr.
A constant infusion rate must be maintained with an infusion pump in order to assure proper dosage control. Care must be taken to avoid overdosage (respiratory depression) or abrupt cessation of therapy, which may give rise to withdrawal symptoms.
Administration of Morphine Sulfate Injection should be limited to use by those familiar with the management of respiratory depression.
NOTE: Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.
EXAMPLES OF INFUSION PREPARATION:
| Concentrate | Diluent | Final Concentration |
|---|---|---|
| Morphine Sulfate Injection, USP | Dextrose 5% in Water | Morphine Sulfate |
| 25 mg/mL | ||
| 10 mL | 490 mL | 0.5 mg/mL |
| 20 mL | 480 mL | 1.0 mg/mL |
| 40 mL | 960 mL | 1.0 mg/mL |
| Morphine Sulfate Injection, USP | ||
| 50 mg/mL | ||
| 10 mL | 990 mL | 0.5 mg/mL |
| 20 mL | 980 mL | 1.0 mg/mL |
Chat online with Pfizer Medical Information regarding your inquiry on a Pfizer medicine.
*Speak with a Pfizer Medical Information Professional regarding your medical inquiry. Available 9AM-5PM ET Monday to Friday; excluding holidays.
Submit a medical question for Pfizer prescription products.
Pfizer Safety
To report an adverse event related to the Pfizer-BioNTech COVID-19 Vaccine, and you are not part of a clinical trial* for this product, click the link below to submit your information:
Pfizer Safety Reporting Site*If you are involved in a clinical trial for this product, adverse events should be reported to your coordinating study site.
If you cannot use the above website, or would like to report an adverse event related to a different Pfizer product, please call Pfizer Safety at (800) 438-1985.
FDA Medwatch
You may also contact the U.S. Food and Drug Administration (FDA) directly to report adverse events or product quality concerns either online at www.fda.gov/medwatch or call (800) 822-7967.